Key regions: Australia, Japan, United States, Germany, Europe
The Anti-Coagulants market in G20 countries has been experiencing significant growth in recent years.
Customer preferences: The increasing prevalence of cardiovascular diseases, including stroke and heart attacks, has led to a growing demand for anti-coagulants in the G20 countries. Additionally, the aging population and the rise in obesity rates have contributed to the growth of the Anti-Coagulants market.
Trends in the market: In the United States, the Anti-Coagulants market is dominated by newer oral anticoagulants, which have been gaining popularity due to their ease of use and lower risk of bleeding compared to traditional anticoagulants. In Europe, there has been a shift towards the use of direct oral anticoagulants as first-line therapy for the treatment of venous thromboembolism. In Japan, the market is dominated by warfarin, which has been widely used for decades.
Local special circumstances: In China, the Anti-Coagulants market is expected to experience significant growth due to the country's aging population and the high prevalence of cardiovascular diseases. The government's efforts to expand access to healthcare and improve the quality of care are also expected to contribute to the growth of the market. In India, the market is dominated by vitamin K antagonists, which are cheaper than newer oral anticoagulants and therefore more accessible to the general population.
Underlying macroeconomic factors: The increasing prevalence of cardiovascular diseases and the aging population are expected to continue driving the growth of the Anti-Coagulants market in the G20 countries. Additionally, the growing demand for personalized medicine and the development of new anticoagulants are expected to further fuel the growth of the market. However, the high cost of newer oral anticoagulants and the increasing competition in the market may pose challenges to the growth of the Anti-Coagulants market in the future.
Data coverage:
Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.Modeling approach / Market size:
Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.Forecasts:
In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.Additional notes:
Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.
Mon - Fri, 9am - 6pm (EST)
Mon - Fri, 9am - 5pm (SGT)
Mon - Fri, 10:00am - 6:00pm (JST)
Mon - Fri, 9:30am - 5pm (GMT)
Mon - Fri, 9am - 6pm (EST)
